Mel is a Principal Scientist at Bristol Myers Squibb ( BMS) and has over 12 years experience in analytical development using multiple biological models with an emphasis in flow cytometry and cell based potency methods. He joined Juno Therapeutics in 2014 and became part of BMS as part of the Juno/Celgene integration in 2019. He currently works in the Potency and Functional Characterization department of Cell Therapy Development Operations of BMS as a matrix-leader for inter-disciplinary efforts supporting both clinical and commercial programs.
Mel resides with his wife and their many animals in the Greater Seattle area.